Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. PotlatchDeltic Corporation

15.5% sales growth and 6.43% return on equity

PotlatchDeltic (NASDAQ:PCH) is a leading Real Estate Investment Trust (REIT) that owns nearly 1.8 million acres of timberlands in Alabama, Arkansas, Idaho, Louisiana, Minnesota and Mississippi.

PotlatchDeltic Corporation’s sales growth this year is expected to be 23.8% and a negative 0.8% for next year.

Year-on-year quarterly revenue growth grew by 38.3%, now sitting on 906.98M for the twelve trailing months.

PotlatchDeltic Corporation’s sales growth for the next quarter is 15.5%. The company’s growth estimates for the current quarter and the next is 366.7% and 332%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.43%.

Volatility

PotlatchDeltic Corporation’s last day, last week, and last month’s average volatility was a negative 1.82%, a positive 0.12%, and a positive 0.23%, respectively.

PotlatchDeltic Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 1.73%, 2.86%, and 2.71%, respectively.

PotlatchDeltic Corporation’s Stock Yearly Top and Bottom Value

PotlatchDeltic Corporation’s stock is valued at $50.09 at 07:22 EST, below its 52-week high of $52.60 and way above its 52-week low of $22.40.

PotlatchDeltic Corporation’s Moving Average

PotlatchDeltic Corporation’s worth is above its 50-day moving average of $48.50 and way higher than its 200-day moving average of $44.39.

2. Catalyst Pharmaceuticals

5.5% sales growth and 60.93% return on equity

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals’s sales growth this year is expected to be 15.7% and 13.3% for next year.

Year-on-year quarterly revenue growth declined by 5.1%, now sitting on 118.18M for the twelve trailing months.

Catalyst Pharmaceuticals’s sales growth for the next quarter is 5.5%. The company’s growth estimates for the present quarter and the next is 12.5% and negative -20%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.93%.

Volatility

Catalyst Pharmaceuticals’s last day, last week, and last month’s average volatility was 3.07%, 0.84%, and 0.02%, respectively.

Catalyst Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 6.76%, 4.24%, and 4.37%, respectively.

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $3.69 at 07:22 EST, way below its 52-week high of $5.28 and way above its 52-week low of $2.55.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is higher than its 50-day moving average of $3.54 and higher than its 200-day moving average of $3.61.

3. Ericsson

16.1% sales growth and 18.65% return on equity

Telefonaktiebolaget LM Ericsson (publ) provides information and communications technology solutions for service providers.

Ericsson’s sales growth this year is anticipated to be 9.6% and 6.1% for next year.

Year-on-year quarterly revenue growth grew by 0.6%, now sitting on N/A for the twelve trailing months.

Ericsson’s sales growth for the next quarter is 16.1%. The company’s growth estimates for the ongoing quarter and the next is 69.2% and 75%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.65%.

Volatility

Ericsson’s last day, last week, and last month’s average volatility was a positive 0.50%, a positive 0.18%, and a negative 0.18%, respectively.

Ericsson’s last day, last week, and last month’s high and low average amplitude percentage was 1.08%, 1.42%, and 1.43%, respectively.

Ericsson’s Stock Yearly Top and Bottom Value

Ericsson’s stock is valued at $12.06 at 07:22 EST, below its 52-week high of $12.61 and way above its 52-week low of $6.15.

Ericsson’s Moving Average

Ericsson’s value is below its 50-day moving average of $12.07 and higher than its 200-day moving average of $11.33.

4. First Bancorp

7.6% sales growth and 9.18% return on equity

First Bancorp operates as the bank holding company for First Bank that provides banking products and services for individuals and small to medium-sized businesses primarily in North Carolina and northeastern South Carolina.

First Bancorp’s sales growth this year is expected to be 6.2% and a negative 2.6% for next year.

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 258.77M for the twelve trailing months.

First Bancorp’s sales growth for the next quarter is 7.6%. The company’s growth estimates for the current quarter and the next is 7% and 16.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.18%.

Volatility

First Bancorp’s last day, last week, and last month’s average volatility was a negative 0.91%, a positive 1.41%, and a positive 0.36%, respectively.

First Bancorp’s last day, last week, and last month’s high and low average amplitude percentage was 9.15%, 5.00%, and 3.22%, respectively.

First Bancorp’s Stock Yearly Top and Bottom Value

First Bancorp’s stock is valued at $36.19 at 07:22 EST, below its 52-week high of $38.71 and way above its 52-week low of $17.32.

First Bancorp’s Moving Average

First Bancorp’s worth is above its 50-day moving average of $33.60 and way above its 200-day moving average of $25.52.

LEAVE A REPLY

Please enter your comment!
Please enter your name here